Voyager Acquisition Corp. and VERAXA Biotech Announce Business Combination

Winston & Strawn represented Voyager Acquisition Corp. in its announced business combination agreement with VERAXA Biotech AG, a biopharmaceutical company developing next-generation antibody-based cancer therapies. The combination will result in VERAXA becoming a publicly traded company on Nasdaq under the ticker symbol “VERX”, with a pre-money equity valuation of $1.3 billion and up to $253 million in cash held in trust by Voyager. The transaction is expected to close in the fourth quarter of 2025, subject to regulatory and shareholder approvals.

VERAXA’s proprietary BiTAC platform supports a pipeline of antibody-drug conjugates (ADCs) and bispecific T-cell engagers (TCEs), offering a novel approach to treating solid tumors with improved safety and efficacy. The merger reflects Voyager’s focus on identifying and advancing innovative life sciences companies poised for long-term growth.